The Schroder Institutional UK Equity Fund's investment objective is to achieve capital growth through investment in UK equities, although considerable attention will be paid to maintaining a steady growth in income distributions.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 6.8% |
Royal Dutch Shell | 6.0% |
Unilever | 5.9% |
BG Group | 5.1% |
Vodafone | 5.0% |
HSBC Holdings | 4.4% |
BP | 4.4% |
Anglo American | 4.2% |
AstraZeneca | 3.7% |
Centrica | 3.3% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 6.8% |
Royal Dutch Shell | 6.0% |
Unilever | 5.9% |
BG Group | 5.1% |
Other | 76.2% |
Date | 21-Nov-2024 |
---|---|
NAV | 502.80p |
Currency | GBP |
Change | -0.50p |
% | -0.10% |
YTD change | 37.30p |
YTD % | 8.01% |
Fund Inception | 06/05/1997 |
---|---|
Fund Manager | Jeremy Smith |
TER | - |
Minimum Investment | |
---|---|
Initial | £1000000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.09 |
You are here: research